Senseonics Holdings, Inc. (AMEX:SENS) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SENS is expected to report 3Q20 loss of $ 0.06 per share from revenue of $ 0.54 million.
For the full year, analysts anticipate top line of $ 1.74 million, while looking forward to loss of $ 0.36 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 15.00 million ~ $ 20.00 million
Click Here For More Historical Outlooks Of Senseonics Holdings, Inc.
Previous Quarter Performance
Senseonics Holdings, Inc. reported loss for the second quarter of $ 0.03 per share, from the revenue of $ 0.26 million. Wall street analysts are predicting, SENS to report 2Q20 loss of $ 0.09 per share from revenue of $ 1.43 million. The bottom line results beat street analysts by $ 0.06 or 66.67 percent, at the same time, top line results fell short of analysts by $ 1.17 million or 81.82 percent.
Stock Performance
On Friday, shares of Senseonics Holdings, Inc. has traded high as $ 0.42 and has cracked $ 0.37 on the downward trend, reaching $ 0.41 with volume of 2.30 million shares.
According to the previous trading day, closing price of $ 0.41, representing a 5.56 % increase from the 52 week low of $ 0.36 and a 78.65 % decrease over the 52 week high of $ 1.78.
The company has a market capital of $ 101.56 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Senseonics Holdings, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.senseonics.com
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a collaboration agreement Roche Diabetes Care, Inc.
